BR9506511A - Processo e composiçao para prevenir ou reduzir a severidade de psoriase processo para evitar proliferaçao das células e processo para diagnosticar ou predizir a susceptibilidade á psoriase e vetor - Google Patents

Processo e composiçao para prevenir ou reduzir a severidade de psoriase processo para evitar proliferaçao das células e processo para diagnosticar ou predizir a susceptibilidade á psoriase e vetor

Info

Publication number
BR9506511A
BR9506511A BR9506511A BR9506511A BR9506511A BR 9506511 A BR9506511 A BR 9506511A BR 9506511 A BR9506511 A BR 9506511A BR 9506511 A BR9506511 A BR 9506511A BR 9506511 A BR9506511 A BR 9506511A
Authority
BR
Brazil
Prior art keywords
psoriasis
preventing
severity
diagnosing
reducing
Prior art date
Application number
BR9506511A
Other languages
English (en)
Inventor
Jennie C C Chang
Steven W Brostoff
Dennis J Carlo
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of BR9506511A publication Critical patent/BR9506511A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
BR9506511A 1994-01-14 1995-01-13 Processo e composiçao para prevenir ou reduzir a severidade de psoriase processo para evitar proliferaçao das células e processo para diagnosticar ou predizir a susceptibilidade á psoriase e vetor BR9506511A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/182,967 US6413516B1 (en) 1989-03-21 1994-01-14 Peptides and methods against psoriasis
PCT/US1995/000658 WO1995019375A1 (en) 1994-01-14 1995-01-13 Peptides and methods against psoriasis

Publications (1)

Publication Number Publication Date
BR9506511A true BR9506511A (pt) 1997-09-09

Family

ID=22670842

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9506511A BR9506511A (pt) 1994-01-14 1995-01-13 Processo e composiçao para prevenir ou reduzir a severidade de psoriase processo para evitar proliferaçao das células e processo para diagnosticar ou predizir a susceptibilidade á psoriase e vetor

Country Status (14)

Country Link
US (1) US6413516B1 (pt)
EP (1) EP0738281B1 (pt)
JP (2) JPH09508112A (pt)
CN (1) CN1138865A (pt)
AT (1) ATE227738T1 (pt)
BR (1) BR9506511A (pt)
CA (1) CA2179280A1 (pt)
DE (1) DE69528817T2 (pt)
ES (1) ES2184791T3 (pt)
FI (1) FI962836A0 (pt)
MX (1) MX9602473A (pt)
NO (1) NO962943L (pt)
NZ (1) NZ279987A (pt)
WO (1) WO1995019375A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
JP2009266963A (ja) * 2008-04-23 2009-11-12 Sumitomo Electric Ind Ltd 窒化物系発光素子、及び半導体発光素子を製造する方法
TW202227495A (zh) * 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
US20240123022A1 (en) 2021-12-16 2024-04-18 Ramakrishna Reddy ISANAKA A stable anti-angiogenic and anti-inflammatory pharmaceutical formulation and pharmaceutical combination for treatment and prevention of psoriasis
CN116466095B (zh) * 2023-06-15 2023-09-01 朗肽生物制药股份有限公司 一种多肽及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003947A1 (en) * 1984-03-01 1985-09-12 The Board Of Trustees Of The Leland Stanford Jr. U T-cell receptor-specific for antigen polypeptides and related polynucleotides
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
IL95125A (en) * 1989-07-19 1995-07-31 Vandenbark Arthur Allen T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
JPH06511241A (ja) 1991-09-23 1994-12-15 ジェネンテク，インコーポレイテッド 自己免疫疾患の診断および治療
WO1993012814A2 (en) * 1991-12-24 1993-07-08 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Also Published As

Publication number Publication date
ATE227738T1 (de) 2002-11-15
AU697910B2 (en) 1998-10-22
NO962943L (no) 1996-09-13
CA2179280A1 (en) 1995-07-20
FI962836A (fi) 1996-07-12
EP0738281A1 (en) 1996-10-23
MX9602473A (es) 1997-05-31
DE69528817T2 (de) 2003-09-11
NO962943D0 (no) 1996-07-12
WO1995019375A1 (en) 1995-07-20
AU1728295A (en) 1995-08-01
NZ279987A (en) 1999-09-29
ES2184791T3 (es) 2003-04-16
US6413516B1 (en) 2002-07-02
JP2001288108A (ja) 2001-10-16
CN1138865A (zh) 1996-12-25
FI962836A0 (fi) 1996-07-12
JPH09508112A (ja) 1997-08-19
DE69528817D1 (de) 2002-12-19
EP0738281B1 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
ATE491180T1 (de) Transaktionserkennung und vorhersage unter verwendung normaler ausdrücke
Langsford et al. The cellulase system of Cellulomonas fimi
DK1034260T3 (da) Hidtil ukendt DNA-kloningsmetode under anvendelse af E.coli-RECE/RECT-rekombinationssystemet
BR9808545A (pt) ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
DK0832245T3 (da) Rekombinant hexoseoxidase, en fremgangsmåde til at fremstille samme samt anvendelse af et sådan enzym
WO1999024463A3 (en) Signal peptide-containing proteins
MX9603002A (es) Procedimiento para la preparacion de virus asociados a los adenovirus (aav), recombinantes, y usos de los mismos.
ATE359509T1 (de) Ersatz für zielobjekte und verbesserten referenzplatten
BR9506511A (pt) Processo e composiçao para prevenir ou reduzir a severidade de psoriase processo para evitar proliferaçao das células e processo para diagnosticar ou predizir a susceptibilidade á psoriase e vetor
Mishto et al. Modeling the in Vitro 20S Proteasome Activity: The Effect of PA28–αβ and of the Sequence and Length of Polypeptides on the Degradation Kinetics
Pollitt et al. Characterisation of the alpha 1-protease inhibitor system in Thoroughbred horse plasma by horizontal two-dimensional (ISO-DALT) electrophoresis. 1. Protein staining.
Koch et al. A simple immunoblotting method after separation of proteins in agarose gel
BR0015365A (pt) Sistema e método de otimização de processo baseado em internet
TR200000288T2 (tr) İnsülin C-peptidin rekombinan ekspresyonu.
WO2000005374A3 (en) Molecules associated with cell proliferation
Luduena et al. Characterization of KB cell alkaline phosphatase. Evidence of similarity to placental alkaline phosphatase.
PT865609E (pt) Processos para o diagnostico e terapia de carcinomas do epitelio escamoso
WO2000028032A3 (en) Human cell surface receptor proteins
ATE273390T1 (de) Säugertier edg-7 rezeptor homologen
NO960341L (no) Rekombinant C140-reseptor og dens agonister og antagonister
WO1998055509A3 (en) Two human dnaj-like proteins
NO963366L (no) Peptider og fremgangsmåte for behandling av diabetes
WO2000021986A3 (en) Matrix-remodeling genes
ATE186553T1 (de) Competitives enzym-testverfahren zum nachweis von phosphothioaten
Belcheva et al. Agonist-induced desensitization and down-regulation of δ opioid receptors alter the levels of their 125I-β-endorphin cross-linked products in subcellular fractions from NG108-15 cells

Legal Events

Date Code Title Description
FC Decision: refusal